Back to Search
Start Over
A cat with myelodysplastic syndrome by administration of the methylation inhibitor Azacytidine.
- Source :
-
The Journal of veterinary medical science [J Vet Med Sci] 2022 Jan 24; Vol. 84 (1), pp. 142-148. Date of Electronic Publication: 2021 Dec 06. - Publication Year :
- 2022
-
Abstract
- A 5-year-old female cat with nonregenerative anemia and thrombocytopenia was diagnosed with myelodysplastic syndromes (MDS), since peripheral blood and bone marrow (BM) examination revealed various dysplasias and a blast ratio of 19%. Chemotherapy with azacytidine (AZA; 70-35 mg/m <superscript>2</superscript> , 3-5 days, three cycles) and treatment with prednisolone, antibiotics, and vitamin K2, and blood transfusion were performed. On day 106, blast cells and dysplasia had decreased in the BM, and the cat remained alive for at least 1,474 days. This report is the first on feline MDS treated with AZA, suggesting appropriate drug dosage, interval and effective combination should be investigated and the pharmacological and cell biological mechanisms needs to be elucidated in the future.
Details
- Language :
- English
- ISSN :
- 1347-7439
- Volume :
- 84
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- The Journal of veterinary medical science
- Publication Type :
- Academic Journal
- Accession number :
- 34866071
- Full Text :
- https://doi.org/10.1292/jvms.20-0352